171 related articles for article (PubMed ID: 8137461)
21. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
[TBL] [Abstract][Full Text] [Related]
22. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
Kelland LR; Murrer BA; Abel G; Giandomenico CM; Mistry P; Harrap KR
Cancer Res; 1992 Feb; 52(4):822-8. PubMed ID: 1737343
[TBL] [Abstract][Full Text] [Related]
23. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
24. The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.
Ormerod MG; Orr RM; O'Neill CF; Chwalinski T; Titley JC; Kelland LR; Harrap KR
Br J Cancer; 1996 Dec; 74(12):1935-43. PubMed ID: 8980393
[TBL] [Abstract][Full Text] [Related]
25. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
Kralovánszky J; Prajda N; Kerpel-Fronius S; Gál F; Kiss F
Cancer Chemother Pharmacol; 1988; 21(1):40-4. PubMed ID: 3277733
[TBL] [Abstract][Full Text] [Related]
26. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
28. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
[TBL] [Abstract][Full Text] [Related]
29. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
30. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
[TBL] [Abstract][Full Text] [Related]
31. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Anticancer Drug Des; 1994 Oct; 9(5):425-34. PubMed ID: 7945726
[TBL] [Abstract][Full Text] [Related]
32. Platinum coordination complexes which circumvent cisplatin resistance.
Harrap KR; Kelland LR; Jones M; Goddard PM; Orr RM; Morgan SE; Murrer BA; Abrams MJ; Giandomenico CM; Cobbleigh T
Adv Enzyme Regul; 1991; 31():31-43. PubMed ID: 1877393
[TBL] [Abstract][Full Text] [Related]
33. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
34. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
[TBL] [Abstract][Full Text] [Related]
35. Platinum concentrations in uterus and serum after internal iliac arterial infusion of platinum compounds in rabbits.
Kigawa J; Minagawa Y; Itamochi H; Kanamori Y; Ishihara H; Terakawa N
Obstet Gynecol; 1995 Aug; 86(2):265-8. PubMed ID: 7617358
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)].
Sova P; Chladek J; Zak F; Mistr A; Kroutil A; Semerad M; Slovak Z
Int J Pharm; 2005 Jan; 288(1):123-9. PubMed ID: 15607264
[TBL] [Abstract][Full Text] [Related]
37. The tissue distribution in rats of [195mPt]carboplatin following intravenous, intraperitoneal and oral administration.
Tinker N; De Spiegeleer B; Sharma H; Jackson H; McAuliffe C; Reman JP
Int J Rad Appl Instrum B; 1990; 17(4):427-36. PubMed ID: 2201668
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.
Kizu R; Higashi S; Kidani Y; Miyazaki M
Cancer Chemother Pharmacol; 1993; 31(6):475-80. PubMed ID: 8453687
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
40. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]